

**HepCBC Hepatitis C Education and Prevention Society**  
**Patient Group recommendation for Holkira Pak™**  
**February 23, 2016**

**General Recommendations:**

- (a) HepCBC supports the CDEC recommendations that all patients with CHC should be considered for treatment, regardless of fibrosis score. We recognise priority needs to be given to those with advanced liver disease, according to the concept of Treatment as Prevention of morbidity/mortality. However there is also clear evidence that the sooner hepatitis C treatment is given, the greater the chance of achieving SVR, the greater chance that liver cancer (and cancer in general), liver failure and transplant, plus other morbidities and mortality will be prevented, and the greater number of QALYs gained.
- (b) HepCBC also supports the addition of one-time-only age-cohort testing for hepatitis C to the current Canadian hepatitis screening guidelines. This action could result in identifying and being able to treat almost every Canadian with hepatitis C. This would greatly enhance the total benefit of these medications to our society as well as providing a good rationale for the TCPA to negotiate lower prices per treatment.

**Recommendation for: Holkira Pak™ (treatment for CHC, genotype 1):**

HepCBC supports the CDEC recommendation for Holkira Pak™ as an approved treatment for CHC genotype 1 patients with modifications as follows:

1. Genotype 1a:

- paritaprevir/ritonavir/ombitasvir + dasabuvir + ribavirin for 12 weeks (without cirrhosis)
- paritaprevir/ritonavir/ombitasvir + dasabuvir + ribavirin for 12-24 weeks (with cirrhosis)

2. Genotype 1b:

- paritaprevir/ritonavir/ombitasvir + dasabuvir for 12 weeks (without cirrhosis)
- paritaprevir/ritonavir/ombitasvir + dasabuvir + ribavirin for 12 weeks (with cirrhosis)

The recommendations for Holkira Pak™ are supported by:

EASL guidelines:

<http://www.easl.eu/medias/cpg/HEPC-2015/Full-report.pdf>

AASLD guidelines:

<http://www.hcvguidelines.org/>

CASL guidelines:

[http://www.liver.ca/files/Professional Education Partnerships/Information Resources for HCP/CASL Hep C Consensus Guidelines Update - Jan 2015.pdf](http://www.liver.ca/files/Professional_Education_Partnerships/Information_Resources_for_HCP/CASL_Hep_C_Consensus_Guidelines_Update_-_Jan_2015.pdf)